SAB Biotherapeutics, Inc.

SABS · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
124
SEC Filings

Business Summary

PART I . Business Overview We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be...

Next Earnings

Q2 FY2026 — expected 2026-09-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSABSdiscussed_in_filing Cybersecurity
topic_mentionSABSdiscussed_in_filing Cybersecurity
topic_mentionSABSdiscussed_in_filing Healthcare & Bio
topic_mentionSABSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-092025-12-310001833214-26-000003EDGAR102K words
2025-03-312024-12-310000950170-25-046994EDGAR—
2024-03-292023-12-310000950170-24-038219EDGAR—
2023-04-142022-12-310001437749-23-010343EDGAR—
2022-03-292021-12-310000950170-22-004935EDGAR—
2021-04-022020-12-310001493152-21-007884EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-142025-09-300001193125-25-280572EDGAR34K words
2025-08-072025-06-300000950170-25-104566EDGAR—
2025-05-092025-03-310000950170-25-067554EDGAR—
2024-11-062024-09-300000950170-24-122443EDGAR—
2024-08-082024-06-300000950170-24-094084EDGAR—
2024-05-202024-03-310000950170-24-062367EDGAR—
2023-11-132023-09-300000950170-23-063076EDGAR—
2023-08-212023-06-300001437749-23-024224EDGAR—
2023-05-152023-03-310001437749-23-014634EDGAR—
2022-11-142022-09-300000950170-22-025094EDGAR—
2022-08-102022-06-300000950170-22-016221EDGAR—
2022-05-122022-03-310000950170-22-009722EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-190001193125-26-114730EDGAR28K words
2026-03-100001193125-26-099376EDGAR—
2026-01-120001193125-26-010515EDGAR—
2026-01-070001193125-26-005487EDGAR—
2025-12-290001193125-25-335267EDGAR—
2025-09-300001193125-25-225119EDGAR—
2025-09-260001193125-25-220721EDGAR—
2025-07-210000950170-25-097078EDGAR—
2025-07-170000950170-25-096645EDGAR—
2025-02-050000950170-25-014627EDGAR—

124 total filings indexed. 96 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001833214
TickerSABS
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a51167b97ccffbc28aae3872648d2b4f15ebe45e7e43895f9cffa8798d57ea25
parent: fe6ba054865f06fb772211ea8921c84392f310afc4dc595200caa2db67a57d21
content hash: 3b5deb94c979d2cddee63e169c35a64cbf4302200c61291403a4a83d112af4cb
signed: 2026-04-13T04:47:18.362Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf